IHS Q4 Earnings, Revenue Rise-March 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

IHS Q4 Earnings, Revenue Rise

Mar 16, 2026 7:52 AM

10:22 AM EDT, 03/16/2026 (MT Newswires) -- IHS Holding ( IHS ) reported Q4 earnings Monday of $0.98 per diluted share, up from $0.81 a year earlier.

Four analysts polled by FactSet expected $0.10.

Revenue for the quarter ended Dec. 31 was $397.8 million, up from $393.2 million a year earlier.

Four analysts surveyed by FactSet expected $428.7 million.

IHS said it is not providing full-year 2026 financial guidance following the announcement of its proposed sale to MTN Group.

Price: 8.18, Change: -0.02, Percent Change: -0.30

Previous page： Self-driving technology startup Avride partners with Hyundai to expand robotaxi fleet Next page： BRIEF-Jazz Pharmaceuticals Upon Termination Of Deal Chimerix Will Be Required To Pay Termination Fee Of $35 Million In Cash

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Self-driving technology startup Avride partners with Hyundai to expand robotaxi fleet

Mar 5, 2025

March 5 (Reuters) - Avride has partnered with Hyundai Motor Co ( HYMTF ) to expand its fleet of robotaxis, and signed a deal with the South Korean automaker to jointly develop and operate self-driving vehicles, the companies said on Wednesday. The Texas-based startup will expand its fleet to 100 Hyundai IONIQ 5 cars this year and further in 2026,...

BRIEF-Jazz Pharmaceuticals Upon Termination Of Deal Chimerix Will Be Required To Pay Termination Fee Of $35 Million In Cash

Mar 5, 2025

March 5 (Reuters) - Chimerix Inc ( CMRX ): * JAZZ PHARMACEUTICALS:UPON TERMINATION OF DEAL UNDER SPECIFIED CIRCUMSTANCES, CHIMERIX WILL BE REQUIRED TO PAY CO TERMINATION FEE OF $35 MILLION IN CASH Source text: Further company coverage: ...

BRIEF-Jazz Pharmaceuticals To Acquire Chimerix

Mar 5, 2025

March 5 (Reuters) - Chimerix ( CMRX ): * JAZZ PHARMACEUTICALS TO ACQUIRE CHIMERIX, FURTHER DIVERSIFYING ONCOLOGY PORTFOLIO * CHIMERIX INC ( CMRX ) - DEAL VALUED AT $935 MILLION, OR $8.55 PER SHARE * CHIMERIX INC ( CMRX ) - JAZZ TO FUND TRANSACTION THROUGH EXISTING CASH AND INVESTMENTS Source text: Further company coverage: ...

Google reports scale of complaints about AI deepfake terrorism content to Australian regulator

Mar 5, 2025

SYDNEY, March 6 (Reuters) - Google has informed Australian authorities it received more than 250 complaints globally over nearly a year that its artificial intelligence software was used to make deepfake terrorism material. The Alphabet-owned tech giant also said it had received dozens of user reports warning that its AI program, Gemini, was being used to create child abuse material,...